MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
Seeking Alpha11/6/2026Neutral
MNKD
MannKind CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.25B
P/E Ratio
—
EPS
$-0.24
Beta
1.09
52W High
$6.51
52W Low
$2.23
50-Day MA
$3.55
200-Day MA
$3.69
Dividend Yield
—
Profit Margin
-18.10%
Forward P/E
28.90
PEG Ratio
4.39
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | $413.37M |
| Gross Profit (TTM) | $313.18M |
| EBITDA | $11.96M |
| Operating Margin | -2.53% |
| Return on Equity | 0.00% |
| Return on Assets | -1.45% |
| Revenue/Share (TTM) | $1.48 |
| Book Value | $-0.12 |
| Price-to-Book | 187.85 |
| Price-to-Sales (TTM) | 3.03 |
| EV/Revenue | 3.63 |
| EV/EBITDA | 70.14 |
| Quarterly Earnings Growth (YoY) | -34.90% |
| Quarterly Revenue Growth (YoY) | 24.00% |
| Shares Outstanding | $321.54M |
| Float | $297.69M |
| % Insiders | 1.47% |
| % Institutions | 56.61% |
Historical Volatility
HV 10-Day
43.80%
HV 20-Day
52.61%
HV 30-Day
69.11%
HV 60-Day
58.58%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($8.08 target)
7
Buy1
HoldLatest News
MannKind Q3 Earnings Call Highlights
MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
MarketBeat11/6/2026Positive
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
GlobeNewsWire10/29/2026Neutral
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often associated with oral nintedanib.
MarketBeat10/20/2026Positive
MannKind to Participate in the Chardan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.
GlobeNewsWire10/14/2026Neutral
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
GlobeNewsWire9/9/2026Neutral
MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
GlobeNewsWire9/2/2026Neutral
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
Zacks Investment Research8/28/2026Positive
MannKind: New Approvals Majorly Increase MannKind's Prospects
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
Seeking Alpha8/13/2026Neutral
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MNKD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026